Person · CIK 1252524
Kurt Von Emster
Director at Iambic Therapeutics and Jasper Therapeutics
Earlier: CymaBay Therapeutics, Vaxcyte, Vera Therapeutics, CRISPR Therapeutics, Pernix Sleep, Facet Biotech and Rigel Pharmaceuticals
Sold on Form 4$75.1M
Noticed on Form 144$263K
Bought on Form 4$14.2M
Companies9
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Iambic Therapeutics IAM | Stock Option (right to buy) exercise $16.00, expires Oct 14, 2036, into Common Stock | Directly | 20,300 | Oct 14, 2026 · Filing · EDGAR |
| Jasper Therapeutics JSPR | Voting Common Stock | Directly | 21,175 | Apr 13, 2023 · Filing · EDGAR |
| Jasper Therapeutics JSPR | Common Stock | By Abingworth Bioventures VII, LP | 5,628,558 | Sep 24, 2021 · Filing · EDGAR |
| Jasper Therapeutics JSPR | Stock Option (Right to Buy exercise $0.63, expires Jul 31, 2036, into Voting Common Stock | Directly | 7,500 | Jul 31, 2026 · Filing · EDGAR |
| CymaBay Therapeutics | Common Stock | See Footnote | 988,931 | Jan 5, 2018 · Filing · EDGAR |
| CymaBay Therapeutics | Common Stock | See footnotes | 131,036 | Dec 18, 2018 · Filing · EDGAR |
| CymaBay Therapeutics | Common Stock | By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | 18,406 | Sep 29, 2023 · Filing · EDGAR |
| Vaxcyte | Common Stock, $0.001 par value per share | See Footnotes | 4,168,718 | Jun 16, 2020 · Filing · EDGAR |
| Vaxcyte | Stock option (right to buy) exercise $21.49, expires Jun 1, 2031, into Common Stock, $0.001 par value per share | Directly | 15,000 | Jun 2, 2021 · Filing · EDGAR |
| Vera Therapeutics | Class A Common Stock | Directly | 17,828 | May 17, 2021 · Filing · EDGAR |
| Vera Therapeutics | Class A Common Stock | See footnote | 2,960,231 | May 18, 2021 · Filing · EDGAR |
| CRISPR Therapeutics | Common Stock | Directly | 90,000 | Jun 5, 2018 · Filing · EDGAR |
| CRISPR Therapeutics | Common Shares | See footnotes | 1,237,202 | Jun 5, 2018 · Filing · EDGAR |
| CRISPR Therapeutics | Common Shares | See Footnote | 1,171,268 | Dec 18, 2018 · Filing · EDGAR |
| CRISPR Therapeutics | Common Stock | By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | 18,316 | Jun 5, 2018 · Filing · EDGAR |
| CRISPR Therapeutics | Stock Option (Right to Buy) exercise $59.31, expires Jun 15, 2028, into Common Shares | Directly | 15,000 | Jun 15, 2018 · Filing · EDGAR |
| Pernix Sleep | Common Stock | See Footnote | 377,358 | Dec 31, 2008 · Filing · EDGAR |
| Rigel Pharmaceuticals | Common Stock | See Footnote | 4,350,516 | Feb 19, 2004 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q3 2023 | $250K | $250K | — |
| Q2 2023 | $14K | $14K | — |
| Q2 2021 | — | — | $8.7M |
| Q2 2020 | — | — | $200K |
| Q4 2018 | $3.1M | Not machine-readable | — |
| Q2 2018 | $35.4M | Not machine-readable | — |
| Q1 2018 | $14.1M | Not machine-readable | $1.5M |
| Q4 2017 | $3.5M | Not machine-readable | — |
| Q3 2017 | $10.8M | Not machine-readable | $1M |
| Q2 2017 | $2.6M | Not machine-readable | — |
| Q4 2016 | — | — | $784K |
| Q3 2012 | $396 | Not machine-readable | — |
| Q4 2010 | $72K | Not machine-readable | — |
| Q2 2010 | $319K | Not machine-readable | — |
| Q3 2009 | — | — | $45K |
| Q2 2007 | $1.4M | Not machine-readable | — |
| Q3 2006 | $43K | Not machine-readable | — |
| Q4 2005 | — | — | $2M |
| Q1 2004 | $3.4M | Not machine-readable | — |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| CymaBay Therapeutics · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 30, 2023 · 1 notice | ||||
| Sep 29, 2023 | 15,921 · ~$250K | Sep 29, 2023 | Sold as noticed Sold 15,921 at $15.68 on Sep 29 · $250K Form 4 | Filing · EDGAR |
| Jasper Therapeutics JSPR · Etrade Financial · No 10b5-1 plan stated · 1 notice | ||||
| Apr 13, 2023 | 9,075 · ~$14K | Apr 13, 2023 | Sold as noticed Sold 9,075 at $1.49 on Apr 13 · $14K Form 4 | Filing · EDGAR |
| Sales without a matching Form 144 · 84 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 62,925 at $29.70 on Dec 18, 2018 · $1.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 53,492 at $7.43 on Dec 18, 2018 · $397K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 3,009 at $33.17 on Dec 17, 2018 · $100K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 88,889 at $8.17 on Dec 17, 2018 · $726K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 920 at $12.51 on Jun 5, 2018 · $12K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 920 at $12.51 on Jun 5, 2018 · $12K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 8,900 at $52.20 on May 14, 2018 · $465K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 20,881 at $52.93 on May 14, 2018 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 53,927 at $53.86 on May 14, 2018 · $2.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 126,901 at $54.99 on May 14, 2018 · $7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 73,144 at $55.72 on May 14, 2018 · $4.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 116,247 at $56.90 on May 14, 2018 · $6.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 8,633 at $51.73 on May 11, 2018 · $447K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 127,890 at $52.46 on May 11, 2018 · $6.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 113,477 at $53.36 on May 11, 2018 · $6.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 13,353 at $15.51 on Mar 5, 2018 · $207K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 68,712 at $14.49 on Feb 15, 2018 · $996K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 162,979 at $13.69 on Feb 14, 2018 · $2.2M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 55,078 at $13.51 on Feb 13, 2018 · $744K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 40,763 at $12.35 on Feb 7, 2018 · $503K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 18,831 at $12.14 on Feb 5, 2018 · $229K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 2,000 at $12.11 on Feb 2, 2018 · $24K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 88,098 at $12.15 on Feb 1, 2018 · $1.1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 12,300 at $12.23 on Jan 31, 2018 · $150K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 85,339 at $12.22 on Jan 30, 2018 · $1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 39,438 at $12.18 on Jan 25, 2018 · $480K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 138,253 at $10.40 on Jan 22, 2018 · $1.4M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 130,584 at $10.25 on Jan 19, 2018 · $1.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 13,632 at $10.21 on Jan 18, 2018 · $139K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 92,337 at $26.96 on Jan 5, 2018 · $2.5M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 4,300 at $10.21 on Jan 5, 2018 · $44K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 37,754 at $26.76 on Jan 2, 2018 · $1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 173,192 at $9.41 on Dec 22, 2017 · $1.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 50,048 at $9.26 on Nov 10, 2017 · $463K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 4,320 at $9.25 on Nov 1, 2017 · $40K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 52,573 at $9.27 on Oct 31, 2017 · $487K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 6,636 at $9.26 on Oct 30, 2017 · $61K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 70,940 at $7.81 on Oct 3, 2017 · $554K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 37,936 at $7.93 on Oct 2, 2017 · $301K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 120,735 at $8.04 on Sep 29, 2017 · $971K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CymaBay Therapeutics: Sold 90,389 at $8.15 on Sep 28, 2017 · $737K | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 88,011 at $19.79 on Aug 28, 2017 · $1.7M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 14,913 at $19.52 on Aug 25, 2017 · $291K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 7,868 at $19.23 on Aug 24, 2017 · $151K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 7,035 at $18.53 on Aug 23, 2017 · $130K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 10,954 at $18.53 on Aug 22, 2017 · $203K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 1,250 at $18.51 on Aug 21, 2017 · $23K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 1,900 at $18.53 on Aug 18, 2017 · $35K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 13,593 at $18.74 on Aug 17, 2017 · $255K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 20,548 at $19.27 on Aug 16, 2017 · $396K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 25,586 at $19.53 on Aug 15, 2017 · $500K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 29,983 at $19.64 on Aug 14, 2017 · $589K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 19,850 at $18.71 on Aug 8, 2017 · $371K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 15,623 at $18.53 on Aug 7, 2017 · $289K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 3,068 at $18.50 on Aug 4, 2017 · $57K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 47,409 at $17.77 on Aug 3, 2017 · $842K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 264 at $17.50 on Aug 1, 2017 · $5K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 5,248 at $17.51 on Jul 31, 2017 · $92K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 400 at $17.65 on Jul 28, 2017 · $7K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 40,912 at $17.63 on Jul 27, 2017 · $721K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 23,744 at $17.63 on Jul 26, 2017 · $419K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 9,186 at $17.52 on Jul 25, 2017 · $161K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 36,230 at $16.82 on Jul 14, 2017 · $609K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 33,629 at $16.87 on Jul 13, 2017 · $567K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 17,872 at $16.60 on Jul 12, 2017 · $297K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 14,120 at $16.52 on Jul 11, 2017 · $233K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 4,254 at $16.26 on Jul 5, 2017 · $69K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 11,610 at $16.52 on Jun 29, 2017 · $192K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 31,592 at $17.04 on Jun 28, 2017 · $538K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 33,434 at $17.43 on Jun 27, 2017 · $583K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 48,001 at $16.83 on Jun 26, 2017 · $808K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 30,841 at $16.23 on Jun 23, 2017 · $501K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable CRISPR Therapeutics: Sold 1,527 at $16.21 on Jun 22, 2017 · $25K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 1,367 at $0.29 on Sep 5, 2012 · $396 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 26,000 at $2.78 on Dec 2, 2010 · $72K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 42,553 at $7.50 on Apr 30, 2010 · $319K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 36,300 at $14.80 on May 14, 2007 · $537K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 32,060 at $14.62 on May 11, 2007 · $469K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 25,000 at $15.65 on May 10, 2007 · $391K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 100 at $14.09 on Sep 11, 2006 · $1K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 300 at $14.08 on Sep 11, 2006 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 100 at $14.11 on Sep 11, 2006 · $1K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pernix Sleep: Sold 2,589 at $14.00 on Sep 11, 2006 · $36K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Rigel Pharmaceuticals: Sold 172,373 at $20.00 on Feb 19, 2004 · $3.4M | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Jasper Therapeutics JSPR Director · filings 2021 to 2026 · sold $14K · $14K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Grant or award from the company Stock Option (Right to Buy | +7,500 | 7,500 direct | Filing · EDGAR | ||
| Jul 3, 2025 | Grant or award from the company Stock Option (right to buy) | +7,500 | 7,500 direct | Filing · EDGAR | ||
| Jun 6, 2024 | Grant or award from the company Stock Option (right to buy) | +7,500 | 7,500 direct | Filing · EDGAR | ||
| Jun 7, 2023 | Grant or award from the company Stock Option (right to buy) | +47,000 | 47,000 direct | Filing · EDGAR | ||
| Apr 13, 2023 | Open-market or private sale | −9,075 | $1.49 | $14K | 21,175 direct | Filing · EDGAR |
| Oct 12, 2022 | Grant or award from the company | +30,250 | 30,250 direct | Filing · EDGAR | ||
| Mar 21, 2022 | Grant or award from the company Stock Option (right to buy) | +78,045 | 78,045 direct | Filing · EDGAR |
CymaBay Therapeutics Director · filings 2017 to 2024 · sold $17.3M · bought $1M · $250K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 22, 2024 | Returned to the company | −90,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −9,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −9,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −9,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −15,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −7,500 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −16,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −27,705 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −49,245 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −32,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −67,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −25,000 | 0 direct | Filing · EDGAR | ||
| Mar 22, 2024 | Returned to the company Employee Stock Option (right to buy) | −14,010 | 0 direct | Filing · EDGAR | ||
| Jan 24, 2024 | Grant or award from the company Stock Option (right to buy) | +14,010 | 14,010 direct | Filing · EDGAR | ||
| Sep 29, 2023 | Option or RSU exercised or converted | +15,921 | $5.00 | $80K | 105,921 direct | Filing · EDGAR |
| Sep 29, 2023 | Sale under a 10b5-1 plan | −15,921 | $15.68 | $250K | 90,000 direct | Filing · EDGAR |
| Sep 29, 2023 | Option or RSU exercised or converted Employee Stock Option (right to buy) | −6,357 | 0 direct | Filing · EDGAR | ||
| Sep 29, 2023 | Option or RSU exercised or converted Employee Stock Option (right to buy) | −943 | 0 direct | Filing · EDGAR | ||
| Sep 29, 2023 | Option or RSU exercised or converted Stock Appreciation Right | −3,372 | 0 direct | Filing · EDGAR | ||
| Sep 29, 2023 | Option or RSU exercised or converted Employee Stock Option (right to buy) | −5,249 | 0 direct | Filing · EDGAR | ||
| Jan 25, 2023 | Grant or award from the company Stock Option (right to buy) | +25,000 | 25,000 direct | Filing · EDGAR | ||
| Jan 25, 2022 | Grant or award from the company Stock Option (right to buy) | +67,000 | 67,000 direct | Filing · EDGAR | ||
| Jan 26, 2021 | Grant or award from the company Stock Option (right to buy) | +32,000 | 32,000 direct | Filing · EDGAR | ||
| May 15, 2020 | Grant or award from the company Stock Option (Right to Buy) | +49,245 | 49,245 direct | Filing · EDGAR | ||
| Jan 29, 2019 | Grant or award from the company Stock option (right to buy) | +27,705 | 27,705 direct | Filing · EDGAR | ||
| Dec 18, 2018 | Open-market or private sale | −53,492 | $7.43 | $397K | 131,036 See footnotes | Filing · EDGAR |
| Dec 17, 2018 | Open-market or private sale | −88,889 | $8.17 | $726K | 184,528 See footnotes | Filing · EDGAR |
| Jun 5, 2018 | In-the-money option exercised | +2,000 | $5.75 | $12K | 19,236 By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | Filing · EDGAR |
| Jun 5, 2018 | Open-market or private sale | −920 | $12.51 | $12K | 18,316 By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | Filing · EDGAR |
| Jun 5, 2018 | In-the-money option exercised Warrant (right to buy) | −2,000 | 0 By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | Filing · EDGAR | ||
| Mar 5, 2018 | Sale under a 10b5-1 plan | −13,353 | $15.51 | $207K | 273,417 See Footnotes | Filing · EDGAR |
| Feb 15, 2018 | Sale under a 10b5-1 plan | −68,712 | $14.49 | $996K | 286,770 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Sale under a 10b5-1 plan | −162,979 | $13.69 | $2.2M | 355,482 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Sale under a 10b5-1 plan | −55,078 | $13.51 | $744K | 518,461 See Footnotes | Filing · EDGAR |
| Feb 7, 2018 | Sale under a 10b5-1 plan | −40,763 | $12.35 | $503K | 419,693 See Footnotes | Filing · EDGAR |
| Feb 5, 2018 | Sale under a 10b5-1 plan | −18,831 | $12.14 | $229K | 460,456 See Footnotes | Filing · EDGAR |
| Feb 2, 2018 | Sale under a 10b5-1 plan | −2,000 | $12.11 | $24K | 479,287 See Footnotes | Filing · EDGAR |
| Feb 1, 2018 | Sale under a 10b5-1 plan | −88,098 | $12.15 | $1.1M | 481,287 See Footnotes | Filing · EDGAR |
| Jan 31, 2018 | Sale under a 10b5-1 plan | −12,300 | $12.23 | $150K | 569,385 See Footnotes | Filing · EDGAR |
| Jan 30, 2018 | Sale under a 10b5-1 plan | −85,339 | $12.22 | $1M | 581,685 See Footnotes | Filing · EDGAR |
| Jan 25, 2018 | Sale under a 10b5-1 plan | −39,438 | $12.18 | $480K | 667,024 See Footnotes | Filing · EDGAR |
| Jan 24, 2018 | Grant or award from the company Stock Option (right to buy) | +16,000 | 16,000 direct | Filing · EDGAR | ||
| Jan 22, 2018 | Sale under a 10b5-1 plan | −138,253 | $10.40 | $1.4M | 706,462 See Footnotes | Filing · EDGAR |
| Jan 19, 2018 | Sale under a 10b5-1 plan | −130,584 | $10.25 | $1.3M | 844,715 See Footnotes | Filing · EDGAR |
| Jan 18, 2018 | Sale under a 10b5-1 plan | −13,632 | $10.21 | $139K | 975,299 See Footnotes | Filing · EDGAR |
| Jan 5, 2018 | Sale under a 10b5-1 plan | −4,300 | $10.21 | $44K | 988,931 See Footnote | Filing · EDGAR |
| Dec 22, 2017 | Sale under a 10b5-1 plan | −173,192 | $9.41 | $1.6M | 993,231 See Footnote | Filing · EDGAR |
| Nov 10, 2017 | Sale under a 10b5-1 plan | −50,048 | $9.26 | $463K | 1,166,423 See Footnote | Filing · EDGAR |
| Nov 1, 2017 | Sale under a 10b5-1 plan | −4,320 | $9.25 | $40K | 1,216,471 See Footnote | Filing · EDGAR |
| Oct 31, 2017 | Sale under a 10b5-1 plan | −52,573 | $9.27 | $487K | 1,220,791 See Footnote | Filing · EDGAR |
| Oct 30, 2017 | Sale under a 10b5-1 plan | −6,636 | $9.26 | $61K | 1,273,364 See Footnote | Filing · EDGAR |
| Oct 3, 2017 | Open-market or private sale | −70,940 | $7.81 | $554K | 1,280,000 See Footnote | Filing · EDGAR |
| Oct 2, 2017 | Open-market or private sale | −37,936 | $7.93 | $301K | 1,350,940 See Footnote | Filing · EDGAR |
| Sep 29, 2017 | Open-market or private sale | −120,735 | $8.04 | $971K | 1,388,876 See Footnote | Filing · EDGAR |
| Sep 28, 2017 | Open-market or private sale | −90,389 | $8.15 | $737K | 1,509,611 See Footnote | Filing · EDGAR |
| Jul 19, 2017 | Open-market or private purchase | +153,846 | $6.50 | $1M | 1,753,846 See Footnotes | Filing · EDGAR |
Vaxcyte Director · filings 2020 to 2021 · bought $200K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 2, 2021 | Grant or award from the company Stock option (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted | +2,185,415 | 2,185,415 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted | +1,217,074 | 3,402,489 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted | +454,812 | 3,857,301 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted | +298,917 | 4,156,218 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Open-market or private purchase | +12,500 | $16.00 | $200K | 4,168,718 See Footnotes | Filing · EDGAR |
| Jun 16, 2020 | Derivative converted Series A Preferred Stock | −2,185,415 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted Series B Preferred Stock | −1,217,074 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted Series C Preferred Stock | −454,812 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2020 | Derivative converted Series D Preferred Stock | −298,917 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 11, 2020 | Grant or award from the company Stock option (right to buy) | +40,000 | 40,000 direct | Filing · EDGAR |
Vera Therapeutics Director · filings 2021 to 2021 · bought $8.7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 18, 2021 | Derivative converted | +2,187,504 | 2,187,504 See footnote | Filing · EDGAR | ||
| May 18, 2021 | Open-market or private purchase | +772,727 | $11.00 | $8.5M | 2,960,231 See footnote | Filing · EDGAR |
| May 18, 2021 | Derivative converted Series C Preferred Stock | −2,187,504 | 0 See footnote | Filing · EDGAR | ||
| May 17, 2021 | Open-market or private purchase | +17,828 | $12.04 | $215K | 17,828 direct | Filing · EDGAR |
| May 13, 2021 | Grant or award from the company Stock Option (right to buy) | +9,925 | 9,925 direct | Filing · EDGAR |
CRISPR Therapeutics Director · filings 2016 to 2019 · sold $52.5M · bought $2.3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 18, 2018 | Open-market or private sale | −62,925 | $29.70 | $1.9M | 1,171,268 See Footnote | Filing · EDGAR |
| Dec 17, 2018 | Open-market or private sale | −3,009 | $33.17 | $100K | 1,234,193 See Footnote | Filing · EDGAR |
| Jun 15, 2018 | Grant or award from the company Stock Option (Right to Buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Jun 5, 2018 | In-the-money option exercised | −2,000 | $5.75 | $12K | 19,236 By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | Filing · EDGAR |
| Jun 5, 2018 | Open-market or private sale | −920 | $12.51 | $12K | 18,316 By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | Filing · EDGAR |
| Jun 5, 2018 | In-the-money option exercised Warrant (right to buy) | −2,000 | 0 By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | Filing · EDGAR | ||
| May 14, 2018 | Open-market or private sale | −116,247 | $56.90 | $6.6M | 1,520,955 See Footnote | Filing · EDGAR |
| May 14, 2018 | Open-market or private sale | −73,144 | $55.72 | $4.1M | 1,447,811 See Footnote | Filing · EDGAR |
| May 14, 2018 | Open-market or private sale | −126,901 | $54.99 | $7M | 1,320,910 See Footnote | Filing · EDGAR |
| May 14, 2018 | Open-market or private sale | −53,927 | $53.86 | $2.9M | 1,266,983 See Footnote | Filing · EDGAR |
| May 14, 2018 | Open-market or private sale | −20,881 | $52.93 | $1.1M | 1,246,102 See Footnote | Filing · EDGAR |
| May 14, 2018 | Open-market or private sale | −8,900 | $52.20 | $465K | 1,237,202 See Footnote | Filing · EDGAR |
| May 11, 2018 | Open-market or private sale | −113,477 | $53.36 | $6.1M | 1,773,725 See Footnote | Filing · EDGAR |
| May 11, 2018 | Open-market or private sale | −127,890 | $52.46 | $6.7M | 1,645,835 See Footnote | Filing · EDGAR |
| May 11, 2018 | Open-market or private sale | −8,633 | $51.73 | $447K | 1,637,202 See Footnote | Filing · EDGAR |
| Jan 5, 2018 | Open-market or private purchase | +65,934 | $22.75 | $1.5M | 1,887,202 See Footnote | Filing · EDGAR |
| Jan 5, 2018 | Sale under a 10b5-1 plan | −92,337 | $26.96 | $2.5M | 1,821,268 See Footnote | Filing · EDGAR |
| Jan 2, 2018 | Sale under a 10b5-1 plan | −37,754 | $26.76 | $1M | 1,913,605 See Footnote | Filing · EDGAR |
| Aug 28, 2017 | Sale under a 10b5-1 plan | −88,011 | $19.79 | $1.7M | 1,951,359 See Footnote | Filing · EDGAR |
| Aug 25, 2017 | Sale under a 10b5-1 plan | −14,913 | $19.52 | $291K | 2,039,370 See Footnote | Filing · EDGAR |
| Aug 24, 2017 | Sale under a 10b5-1 plan | −7,868 | $19.23 | $151K | 2,054,283 See Footnote | Filing · EDGAR |
| Aug 23, 2017 | Sale under a 10b5-1 plan | −7,035 | $18.53 | $130K | 2,062,151 See Footnote | Filing · EDGAR |
| Aug 22, 2017 | Sale under a 10b5-1 plan | −10,954 | $18.53 | $203K | 2,069,186 See Footnote | Filing · EDGAR |
| Aug 21, 2017 | Sale under a 10b5-1 plan | −1,250 | $18.51 | $23K | 2,080,140 See Footnote | Filing · EDGAR |
| Aug 18, 2017 | Sale under a 10b5-1 plan | −1,900 | $18.53 | $35K | 2,081,390 See Footnote | Filing · EDGAR |
| Aug 17, 2017 | Sale under a 10b5-1 plan | −13,593 | $18.74 | $255K | 2,083,290 See Footnote | Filing · EDGAR |
| Aug 16, 2017 | Sale under a 10b5-1 plan | −20,548 | $19.27 | $396K | 2,096,883 See Footnote | Filing · EDGAR |
| Aug 15, 2017 | Sale under a 10b5-1 plan | −25,586 | $19.53 | $500K | 2,117,431 See Footnote | Filing · EDGAR |
| Aug 14, 2017 | Sale under a 10b5-1 plan | −29,983 | $19.64 | $589K | 2,143,017 See Footnote | Filing · EDGAR |
| Aug 8, 2017 | Sale under a 10b5-1 plan | −19,850 | $18.71 | $371K | 2,190,872 See Footnote | Filing · EDGAR |
| Aug 7, 2017 | Sale under a 10b5-1 plan | −15,623 | $18.53 | $289K | 2,210,722 See Footnote | Filing · EDGAR |
| Aug 4, 2017 | Sale under a 10b5-1 plan | −3,068 | $18.50 | $57K | 2,226,345 See Footnote | Filing · EDGAR |
| Aug 3, 2017 | Sale under a 10b5-1 plan | −47,409 | $17.77 | $842K | 2,229,413 See Footnote | Filing · EDGAR |
| Aug 1, 2017 | Sale under a 10b5-1 plan | −264 | $17.50 | $5K | 2,276,822 See Footnote | Filing · EDGAR |
| Jul 31, 2017 | Sale under a 10b5-1 plan | −5,248 | $17.51 | $92K | 2,277,086 See Footnote | Filing · EDGAR |
| Jul 28, 2017 | Sale under a 10b5-1 plan | −400 | $17.65 | $7K | 2,282,334 See Footnote | Filing · EDGAR |
| Jul 27, 2017 | Sale under a 10b5-1 plan | −40,912 | $17.63 | $721K | 2,282,734 See Footnote | Filing · EDGAR |
| Jul 26, 2017 | Sale under a 10b5-1 plan | −23,744 | $17.63 | $419K | 2,323,646 See Footnote | Filing · EDGAR |
| Jul 25, 2017 | Sale under a 10b5-1 plan | −9,186 | $17.52 | $161K | 2,347,390 See Footnote | Filing · EDGAR |
| Jul 14, 2017 | Sale under a 10b5-1 plan | −36,230 | $16.82 | $609K | 2,356,576 See Footnote | Filing · EDGAR |
| Jul 13, 2017 | Sale under a 10b5-1 plan | −33,629 | $16.87 | $567K | 2,392,806 See Footnote | Filing · EDGAR |
| Jul 12, 2017 | Sale under a 10b5-1 plan | −17,872 | $16.60 | $297K | 2,408,563 See Footnote | Filing · EDGAR |
| Jul 11, 2017 | Sale under a 10b5-1 plan | −14,120 | $16.52 | $233K | 2,426,435 See Footnote | Filing · EDGAR |
| Jul 5, 2017 | Sale under a 10b5-1 plan | −4,254 | $16.26 | $69K | 2,440,555 See Footnote | Filing · EDGAR |
| Jun 29, 2017 | Sale under a 10b5-1 plan | −11,610 | $16.52 | $192K | 2,444,809 See Footnote | Filing · EDGAR |
| Jun 28, 2017 | Sale under a 10b5-1 plan | −31,592 | $17.04 | $538K | 2,456,419 See Footnote | Filing · EDGAR |
| Jun 27, 2017 | Sale under a 10b5-1 plan | −33,434 | $17.43 | $583K | 2,488,011 See Footnote | Filing · EDGAR |
| Jun 26, 2017 | Sale under a 10b5-1 plan | −48,001 | $16.83 | $808K | 2,521,445 See Footnote | Filing · EDGAR |
| Jun 23, 2017 | Sale under a 10b5-1 plan | −30,841 | $16.23 | $501K | 2,569,446 See Footnote | Filing · EDGAR |
| Jun 22, 2017 | Sale under a 10b5-1 plan | −1,527 | $16.21 | $25K | 2,600,287 See Footnote | Filing · EDGAR |
| May 31, 2017 | Grant or award from the company Stock Option (Right to Buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Oct 24, 2016 | Derivative converted | +2,354,050 | 2,354,050 See Footnote | Filing · EDGAR | ||
| Oct 24, 2016 | Derivative converted | +191,764 | 2,545,814 See Footnote | Filing · EDGAR | ||
| Oct 24, 2016 | Open-market or private purchase | +56,000 | $14.00 | $784K | 2,601,814 See Footnote | Filing · EDGAR |
| Oct 24, 2016 | Derivative converted Series A-3 Preferred Shares | −2,354,050 | 0 See Footnote | Filing · EDGAR | ||
| Oct 24, 2016 | Derivative converted Series B Preferred Shares | −191,764 | 0 See Footnote | Filing · EDGAR | ||
| Oct 18, 2016 | Grant or award from the company Stock Option (Right to Buy) | +30,000 | 30,000 direct | Filing · EDGAR |
Pernix Sleep Director · filings 2005 to 2013 · sold $1.8M · bought $2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 6, 2013 | Returned to the company | −31,800 | 0 direct | Filing · EDGAR | ||
| Mar 6, 2013 | Returned to the company | −3,214 | 0 By Trust | Filing · EDGAR | ||
| Dec 31, 2012 | Grant or award from the company | +6,541 | 27,679 direct | Filing · EDGAR | ||
| Sep 30, 2012 | Grant or award from the company | +48,103 | 169,105 direct | Filing · EDGAR | ||
| Sep 5, 2012 | Open-market or private sale | −1,367 | $0.29 | $396 | 25,712 By Trust | Filing · EDGAR |
| Jul 2, 2012 | Grant or award from the company | +61,579 | 121,002 direct | Filing · EDGAR | ||
| May 31, 2012 | Grant or award from the company Stock Option (right to buy) | +17,500 | 17,500 direct | Filing · EDGAR | ||
| Apr 2, 2012 | Grant or award from the company | +59,423 | 59,423 direct | Filing · EDGAR | ||
| Jun 1, 2011 | Grant or award from the company Stock Option (right to buy) | +17,500 | 17,500 By trust | Filing · EDGAR | ||
| Dec 2, 2010 | Sale under a 10b5-1 plan | −26,000 | $2.78 | $72K | 27,079 By trust | Filing · EDGAR |
| Jun 9, 2010 | Grant or award from the company Stock Option (right to buy) | +17,500 | 17,500 direct | Filing · EDGAR | ||
| Apr 30, 2010 | Sale under a 10b5-1 plan | −42,553 | $7.50 | $319K | 54,446 direct | Filing · EDGAR |
| Mar 31, 2010 | Grant or award from the company | +1,283 | 53,216 direct | Filing · EDGAR | ||
| Dec 31, 2009 | Grant or award from the company | +8,796 | 51,933 direct | Filing · EDGAR | ||
| Sep 30, 2009 | Grant or award from the company | +3,886 | 43,137 direct | Filing · EDGAR | ||
| Jul 8, 2009 | Open-market or private purchase | +42,553 | $1.05 | $45K | 42,553 By Trust | Filing · EDGAR |
| Jul 8, 2009 | Open-market or private purchase Warrant to purchase common stock (right to buy) | +42,553 | $0.13 | $5K | 42,553 By Trust | Filing · EDGAR |
| Jul 8, 2009 | Grant or award from the company | +42,553 | $1.05 | $45K | 42,553 By Trust | Filing · EDGAR |
| Jul 8, 2009 | Grant or award from the company Warrant to purchase common stock (right to buy) | +42,553 | $0.13 | $5K | 42,553 By Trust | Filing · EDGAR |
| Jun 30, 2009 | Grant or award from the company | +10,000 | 39,251 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Returned to the company Stock Option (right to buy) | −35,000 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +23,333 | 23,333 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Returned to the company Stock Option (right to buy) | −17,500 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +11,666 | 11,666 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Returned to the company Stock Option (right to buy) | −17,500 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +11,666 | 11,666 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Returned to the company Stock Option (right to buy) | −15,000 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +10,000 | 10,000 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Returned to the company Stock Option (right to buy) | −2,500 | 0 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +1,666 | 1,666 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Jun 9, 2009 | Grant or award from the company Stock Option (right to buy) | +2,500 | 2,500 direct | Filing · EDGAR | ||
| Mar 31, 2009 | Grant or award from the company | +28,571 | 29,251 direct | Filing · EDGAR | ||
| Dec 31, 2008 | Grant or award from the company | +543 | 543 direct | Filing · EDGAR | ||
| Jun 11, 2008 | Grant or award from the company Stock Option (right to buy) | +15,000 | 15,000 direct | Filing · EDGAR | ||
| Jun 11, 2008 | Grant or award from the company Stock Option (right to buy) | +2,500 | 2,500 direct | Filing · EDGAR | ||
| May 31, 2007 | Grant or award from the company Stock Option (Right to Buy) | +17,500 | 17,500 direct | Filing · EDGAR | ||
| May 14, 2007 | Open-market or private sale | −36,300 | $14.80 | $537K | 377,358 See Footnote | Filing · EDGAR |
| May 11, 2007 | Open-market or private sale | −32,060 | $14.62 | $469K | 413,658 See Footnote | Filing · EDGAR |
| May 10, 2007 | Open-market or private sale | −25,000 | $15.65 | $391K | 445,718 See Footnote | Filing · EDGAR |
| Sep 11, 2006 | Open-market or private sale | −2,589 | $14.00 | $36K | 471,218 See Footnote | Filing · EDGAR |
| Sep 11, 2006 | Open-market or private sale | −100 | $14.11 | $1K | 471,118 See Footnote | Filing · EDGAR |
| Sep 11, 2006 | Open-market or private sale | −300 | $14.08 | $4K | 470,818 See Footnote | Filing · EDGAR |
| Sep 11, 2006 | Open-market or private sale | −100 | $14.09 | $1K | 470,718 See Footnote | Filing · EDGAR |
| May 31, 2006 | Grant or award from the company Stock options (rights to buy) | +17,500 | 17,500 direct | Filing · EDGAR | ||
| Dec 20, 2005 | Derivative converted | +291,807 | 291,807 See Footnote | Filing · EDGAR | ||
| Dec 20, 2005 | Open-market or private purchase | +182,000 | $11.00 | $2M | 473,807 See Footnote | Filing · EDGAR |
| Dec 20, 2005 | Derivative converted Series C Preferred Stock | −1,750,839 | 0 See Footnote | Filing · EDGAR | ||
| Dec 15, 2005 | Grant or award from the company Stock Option (Right to Buy) | +35,000 | 35,000 direct | Filing · EDGAR |
Facet Biotech Director · filings 2009 to 2010
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 21, 2010 | Returned to the company | −1,667 | $27.00 | $45K | 0 direct | Filing · EDGAR |
| Apr 21, 2010 | Returned to the company Stock Option (Right to Buy) | −16,667 | $27.00 | $450K | 0 direct | Filing · EDGAR |
| Apr 21, 2010 | Returned to the company Stock Option (Right to Buy) | −3,334 | $27.00 | $90K | 0 direct | Filing · EDGAR |
| Apr 20, 2010 | Tendered in a change of control | −8,333 | $27.00 | $225K | 1,667 direct | Filing · EDGAR |
| May 26, 2009 | Grant or award from the company | +1,667 | 10,000 direct | Filing · EDGAR | ||
| May 26, 2009 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +3,334 | 3,334 direct | Filing · EDGAR | ||
| Feb 23, 2009 | Grant or award from the company | +8,333 | 8,333 direct | Filing · EDGAR | ||
| Feb 23, 2009 | Grant or award from the company Non-Qualified Stock Option (right to buy) | +16,667 | 16,667 direct | Filing · EDGAR |
Rigel Pharmaceuticals 10% owner · filings 2003 to 2004 · sold $3.4M
All 118 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 16, 2026 | Form 4 | Iambic Therapeutics IAM | Filing · EDGAR |
| Oct 14, 2026 | Form 3 | Iambic Therapeutics IAM | Filing · EDGAR |
| Aug 4, 2026 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Jul 3, 2025 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Jun 10, 2024 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Mar 22, 2024 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 26, 2024 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Sep 29, 2023 | Form 144 | CymaBay Therapeutics | Filing · EDGAR |
| Sep 29, 2023 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jun 8, 2023 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Apr 14, 2023 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Apr 13, 2023 | Form 144 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Jan 27, 2023 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Oct 13, 2022 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Mar 23, 2022 | Form 4 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Jan 27, 2022 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Oct 1, 2021 | Form 3 | Jasper Therapeutics JSPR | Filing · EDGAR |
| Jun 3, 2021 | Form 4 | Vaxcyte | Filing · EDGAR |
| May 18, 2021 | Form 4 | Vera Therapeutics | Filing · EDGAR |
| May 17, 2021 | Form 4 | Vera Therapeutics | Filing · EDGAR |
| May 13, 2021 | Form 3 | Vera Therapeutics | Filing · EDGAR |
| Feb 1, 2021 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jun 23, 2020 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jun 18, 2020 | Form 4 | Vaxcyte | Filing · EDGAR |
| Jun 16, 2020 | Form 4/A | Vaxcyte | Filing · EDGAR |
| Jun 15, 2020 | Form 4 | Vaxcyte | Filing · EDGAR |
| Jun 11, 2020 | Form 3 | Vaxcyte | Filing · EDGAR |
| Jan 31, 2019 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 18, 2019 | Form 4/A | CRISPR Therapeutics | Filing · EDGAR |
| Dec 19, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Dec 19, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jun 18, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jun 11, 2018 | Form 4/A | CymaBay Therapeutics | Filing · EDGAR |
| Jun 7, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jun 7, 2018 | Form 4/A | CRISPR Therapeutics | Filing · EDGAR |
| Jun 7, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| May 15, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Mar 7, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 20, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 16, 2018 | Form 4/A | CymaBay Therapeutics | Filing · EDGAR |
| Feb 15, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 12, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 9, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 7, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 5, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Feb 1, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 26, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 24, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 22, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 11, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jan 9, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jan 9, 2018 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Jan 4, 2018 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Dec 27, 2017 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Nov 14, 2017 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Nov 3, 2017 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Nov 1, 2017 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Oct 4, 2017 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Oct 2, 2017 | Form 4 | CymaBay Therapeutics | Filing · EDGAR |
| Aug 30, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 28, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 24, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 22, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 18, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 16, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 11, 2017 | Form 4/A | CRISPR Therapeutics | Filing · EDGAR |
| Aug 9, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 7, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Aug 2, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jul 31, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jul 27, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jul 17, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jul 13, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jul 7, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jun 30, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jun 28, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jun 26, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Jun 2, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Feb 10, 2017 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Oct 20, 2016 | Form 4 | CRISPR Therapeutics | Filing · EDGAR |
| Oct 18, 2016 | Form 3 | CRISPR Therapeutics | Filing · EDGAR |
| Mar 8, 2013 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jan 3, 2013 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Oct 2, 2012 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Sep 6, 2012 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jul 3, 2012 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 4, 2012 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Apr 4, 2012 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 3, 2011 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Dec 3, 2010 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 14, 2010 | Form 4 | Pernix Sleep | Filing · EDGAR |
| May 4, 2010 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Apr 23, 2010 | Form 4 | Facet Biotech | Filing · EDGAR |
| Apr 21, 2010 | Form 4 | Facet Biotech | Filing · EDGAR |
| Apr 2, 2010 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jan 5, 2010 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Oct 2, 2009 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jul 14, 2009 | Form 4/A | Pernix Sleep | Filing · EDGAR |
| Jul 10, 2009 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jul 2, 2009 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 10, 2009 | Form 4 | Pernix Sleep | Filing · EDGAR |
| May 28, 2009 | Form 4 | Facet Biotech | Filing · EDGAR |
| Apr 2, 2009 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Feb 24, 2009 | Form 4 | Facet Biotech | Filing · EDGAR |
| Feb 24, 2009 | Form 3 | Facet Biotech | Filing · EDGAR |
| Jan 8, 2009 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 13, 2008 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 4, 2007 | Form 4 | Pernix Sleep | Filing · EDGAR |
| May 16, 2007 | Form 4 | Pernix Sleep | Filing · EDGAR |
| May 14, 2007 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Sep 13, 2006 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Jun 1, 2006 | Form 4/A | Pernix Sleep | Filing · EDGAR |
| Jun 1, 2006 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Feb 7, 2006 | Form 5 | Pernix Sleep | Filing · EDGAR |
| Dec 20, 2005 | Form 4 | Pernix Sleep | Filing · EDGAR |
| Dec 14, 2005 | Form 3 | Pernix Sleep | Filing · EDGAR |
| Feb 23, 2004 | Form 4 | Rigel Pharmaceuticals | Filing · EDGAR |
| Jul 8, 2003 | Form 3 | Rigel Pharmaceuticals | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.